Print | Need Larger Text?

Incident Report

Subform I: General Information

1. Report Type.

New incident report

Incident Report Number: 2022-0825

2. Registrant Information.

Registrant Reference Number: M-345551-01-1

Registrant Name (Full Legal Name no abbreviations): Bayer CropScience Inc.

Address: Suite 200, 160 Quarry Park Boulevard SE

City: CALGARY

Prov / State: AB

Country: Canada

Postal Code: T2C 3G3

3. Select the appropriate subform(s) for the incident.

Scientific Study

4. Date registrant was first informed of the incident.

5. Location of incident.

6. Date incident was first observed.

Product Description

7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.

PMRA Registration No.       PMRA Submission No.       EPA Registration No. Unknown

Product Name: IAF + MRB SC 517.5 (37.5 + 480) G

• Active Ingredient(s)
  • INDAZIFLAM
  • METRIBUZIN

7. b) Type of formulation.

Application Information

8. Product was applied?

Unknown

9. Application Rate.

10. Site pesticide was applied to (select all that apply).

11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).

To be determined by Registrant

12. In your opinion, was the product used according to the label instructions?

Unknown

Subform VII: Scientific Study

1. Study Reference

Title lndaziflam + metribuzin SC 517.5 (37.5 + 480) G: acute toxicity to earthworms (Eisenia fetida) tested in artificial soil with 5 % peat

Date 20-APR-09

2. a) Is an extension needed to translate the document?

No

3. Type of incident identified in the study

Increased health or environmental risk

4. Describe the incident identified in the study (e.g. study demonstrates an increased risk to non-Hodgkin's Lymphoma after exposure to pesticide X)

An acute (14 day) earthworm study was performed with the co-formulation indaziflam+metribuzin. The EC50 generated in this study appears to be 50% lower (when normalized to metribuzin content) than the acute EC50 generated in the 14 day earthworm acute study with metribuzin active ingredient. However, this formulation is not registered in Canada.

5. a) Was the study discontinued before completion?

No

5. b) Provide the reason for discontinuation

6. If the study is ongoing, what is the expected completion date?

For Registrant use only

7. Provide supplemental information here

This formulation is not registered in Canada, and therefore, not relevant for the risk assessment.